A US appeals court on Friday, February 21, revived a lawsuit by Walgreen and Kroger accusing Johnson & Johnson (J&J) of unlawfully restricting access to lower-cost “biosimilar” versions of its drug Remicade.
Reversing a lower court, the 3rd US Circuit Court of Appeals stated contracts Walgreens and Kroger entered into with drug wholesalers gave the pharmacies the right to sue J&J for antitrust violations.
The retailers had lodged their suit in Pennsylvania federal court last year, accusing J&J of illegally shielding its blockbuster drug from competitors and charging artificially inflated prices for the treatment. Their suit cited the same core allegations that had sparked earlier legal action from other players in the pharmaceutical industry, including one from rival drugmaker Pfizer and a proposed class suit lodged by other buyers along the Remicade distribution line.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Kenya’s Competition Authority Proposes Tougher Regulations on Big Tech
May 30, 2024 by
CPI
KKR Secures EU Antitrust Approval for $24 Billion Acquisition of Telecom Italia’s Fixed-Line Network
May 30, 2024 by
CPI
European Court Sides with Tech Giants in Italian Regulatory Dispute
May 30, 2024 by
CPI
US Steel and Nippon Steel Secure International Approvals for $14.9B Merger
May 30, 2024 by
CPI
EU Watchdog Mandates Boardroom Accountability for AI in Banks
May 30, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI